Skip to main content
UniHealth

Doctor search

Alan B Goldsobel, MD

Allergy/Immunology · Redwood City

NPI 1063528321

Medicare standing
Clear
Enrolled, allowed to bill and order, not excluded
Plans that list them
30
6 carriers
Office
1

Offices

1 location · UCSF Health Medical Foundation · 40 clinicians in this group

Looking this up.

Hospitals listed: Dominican Hospital. That is not proof they admit you there this week.

Plans that list them

30 plans · 6 carriers

A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Goldsobel’s office at (650) 701-1882 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.

30 of 30 plans

Plans whose provider directory lists this clinician
Alignment Health Advantage PPO (PPO)Alignment Health PlanListedOct 3, 2026
Alignment Health BreathEasy (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Clarity (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Harmony (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes CalPlus (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Heart & Diabetes Care (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Heart & Diabetes Choice (HMO C-SNP)Alignment Health PlanListedSep 28, 2026
Alignment Health Honor+ Plan (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health My Choice CalCare (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health Silicon (HMO C-SNP)Alignment Health PlanListedOct 3, 2026
Alignment Health Sutter Advantage +More (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health smartHMO (HMO)Alignment Health PlanListedOct 3, 2026
Alignment Health the ONE (HMO)Alignment Health PlanListedOct 3, 2026
Astiva Health C-SNP WOW - NorCal (HMO C-SNP)Astiva HealthListedSep 27, 2026
Astiva Health Premier Plan - NorCal (HMO)Astiva HealthListedSep 27, 2026
Astiva Health Savings Plan - NorCal (HMO)Astiva HealthListedSep 27, 2026
Blue Shield Inspire (HMO)Blue Shield of CaliforniaListedAug 26, 2026
Central Health Classic Care Plan III (HMO)Central Health Medicare PlanListedAug 15, 2026
Central Health Dual Access Plan (HMO D-SNP)Central Health Medicare PlanListedAug 15, 2026
Central Health Embrace Care Plan (HMO C-SNP)Central Health Medicare PlanListed, may be out of dateSep 15, 2025
Central Health Embrace Choice Plan (HMO C-SNP)Central Health Medicare PlanListedAug 15, 2026
Central Health Valor Care Plan (HMO)Central Health Medicare PlanListedAug 15, 2026
Imperial Courage Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Dynamic Plan (HMO)Imperial Health Plan of California, Inc.ListedSep 1, 2026
Imperial Senior Value (HMO C-SNP)Imperial Health Plan of California, Inc.ListedSep 1, 2026
SCAN Balance (HMO C-SNP)SCAN Health PlanListedOct 3, 2026
SCAN Classic (HMO)SCAN Health PlanListedOct 3, 2026
SCAN MyChoice (HMO)SCAN Health PlanListedOct 3, 2026
SCAN Strive (HMO C-SNP)SCAN Health PlanListedOct 3, 2026

California Medical Board record

Licence G39891 · Current

Licensed to practise in California · since 1979 · expires 2028-07-31 · University of Texas Medical Branch at Galveston.

No disciplinary actions, convictions, malpractice judgments or citations in this record.

Hospitals they work in

1 hospital

These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.

  • Dominican HospitalSanta Cruz, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of CommonSpirit Health, which runs 145 hospitals in 19 statesPatients rate it 4 of 5 · 68% would definitely recommend it
    Overall rating: 4 of 5 starsWorse than the national rate — Postoperative sepsis rate: 11.66 (8.02 to 15.3) · 412 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.168, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.169, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.489, Oct 2024 – Sep 2025
See every measure and the patient survey for Dominican Hospital

Behind the star rating — Deaths: 1 better, 7 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 2 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.

Every scored measure at Dominican Hospital
Postoperative sepsis rateComplications and deaths11.66 (8.02 to 15.3) · 412 casesWorseJul 2022 – Jun 2024
Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections0.168BetterOct 2024 – Sep 2025
Central Line Associated Bloodstream Infection (ICU + select Wards)Infections0.169BetterOct 2024 – Sep 2025
Clostridium Difficile (C.Diff)Infections0.489BetterOct 2024 – Sep 2025
Abdominopelvic accidental puncture or laceration rateComplications and deaths1.01 (0.06 to 1.95) · 1,248 casesNo differentJul 2022 – Jun 2024
CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths1.14 (0.85 to 1.43)No differentJul 2022 – Jun 2024
Death rate among surgical inpatients with serious treatable complicationsComplications and deaths134.37 (94.33 to 174.41) · 132 casesNo differentJul 2022 – Jun 2024
Death rate for CABG surgery patientsComplications and deaths2.4 · 54 casesNoneJul 2022 – Jun 2025
Death rate for COPD patientsComplications and deaths7.2 · 137 casesNoneJul 2022 – Jun 2025
Death rate for heart attack patientsComplications and deaths12 · 228 casesNoneJul 2022 – Jun 2025
Death rate for heart failure patientsComplications and deaths10.5 · 534 casesNoneJul 2022 – Jun 2025
Death rate for pneumonia patientsComplications and deaths12.8 · 491 casesNoneJul 2022 – Jun 2025
Death rate for stroke patientsComplications and deaths8.7 · 278 casesNoneJul 2023 – Jun 2025
Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths3.4 · 2,973 casesNoneJul 2024 – Jun 2025
Iatrogenic pneumothorax rateComplications and deaths0.14 (0 to 0.34) · 7,510 casesNo differentJul 2022 – Jun 2024
In-hospital fall-associated fracture rateComplications and deaths0.21 (0.02 to 0.4) · 7,695 casesNo differentJul 2022 – Jun 2024
Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths3.42 (1.44 to 5.4) · 1,594 casesNo differentJul 2022 – Jun 2024
Postoperative acute kidney injury requiring dialysis rateComplications and deaths1.26 (0 to 2.76) · 436 casesNo differentJul 2022 – Jun 2024
Postoperative hemorrhage or hematoma rateComplications and deaths1.85 (0.4 to 3.29) · 1,474 casesNo differentJul 2022 – Jun 2024
Postoperative respiratory failure rateComplications and deaths8.73 (3 to 14.46) · 437 casesNo differentJul 2022 – Jun 2024
Postoperative wound dehiscence rateComplications and deaths1.58 (0.13 to 3.03) · 343 casesNo differentJul 2022 – Jun 2024
Pressure ulcer rateComplications and deaths0.57 (0 to 1.17) · 6,336 casesNo differentJul 2022 – Jun 2024
MRSA BacteremiaInfections0.615No differentOct 2024 – Sep 2025
SSI - Colon SurgeryInfections1.937No differentOct 2024 – Sep 2025
Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits16 · 212 casesNoneJul 2023 – Jun 2025
Heart failure (HF) 30-Day Readmission RateUnplanned return visits22 · 505 casesNoneJul 2023 – Jun 2025
Hospital return days for heart attack patientsUnplanned return visits45 · 237 casesNoneJul 2022 – Jun 2025
Hospital return days for heart failure patientsUnplanned return visits-13.5 · 594 casesNoneJul 2022 – Jun 2025
Hospital return days for pneumonia patientsUnplanned return visits1.9 · 510 casesNoneJul 2022 – Jun 2025
Pneumonia (PN) 30-Day Readmission RateUnplanned return visits16.9 · 473 casesNoneJul 2023 – Jun 2025
Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits5.2 (3.4 to 7.8) · 126 casesNo differentJan 2024 – Dec 2024
Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits13 (9.4 to 17.7) · 126 casesNo differentJan 2024 – Dec 2024
Rate of readmission for CABGUnplanned return visits12.7 · 43 casesNoneJul 2023 – Jun 2025
Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits19.7 · 143 casesNoneJul 2023 – Jun 2025
Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits12.1 (9.4 to 15.4) · 1,585 casesNo differentJan 2022 – Dec 2024
Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits1 (0.7 to 1.3) · 390 casesNo differentJan 2024 – Dec 2024

What patients said (774 patients answered, 23% of those asked)

Patient survey stars by topic at Dominican Hospital
Cleanliness4
Nurse communication4
Doctor communication4
Communication about medicines3
Discharge information4
Overall hospital rating3
Quietness1
Recommend hospital4
Share of patients giving the best answer at Dominican Hospital
Room was "always" clean73%
Nurses "always" communicated well79%
Doctors "always" communicated well81%
Staff "always" explained61%
Yes, staff "did" give patients this information87%
Yes, staff "did" give patients information about help after discharge86%
Doctors "always" explained things so they could understand77%
Doctors "always" listened carefully79%
Doctors "always" treated them with courtesy and respect87%
Patients who gave a rating of "9" or "10" (high)67%
Staff "always" explained new medications75%
Nurses "always" explained things so they could understand76%
Nurses "always" listened carefully76%
Nurses "always" treated them with courtesy and respect85%
"Always" quiet at night32%
"YES", patients would definitely recommend the hospital68%
Staff "always" explained possible side effects48%
Yes, staff "did" give patients information about possible symptoms88%

Original Medicare doctor bills

$73,771

Medicare paid this office $73,771 for 287 people.

This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.

Largest Original Medicare bills
Professional service for preparation and provision of 1 or more antigens44$11,540$14
Short return visit (20+ min)128$11,338$78
Return visit (30+ min)85$10,250$110
Test for allergy using allergenic extract45$7,389$3
New patient visit (45+ min)51$7,319$144
See all 11 services
Every Original Medicare service billed
Professional service for preparation and provision of 1 or more antigens44$11,540$14
Short return visit (20+ min)128$11,338$78
Return visit (30+ min)85$10,250$110
Test for allergy using allergenic extract45$7,389$3
New patient visit (45+ min)51$7,319$144
Professional service for multiple injections of allergen45$6,238$11
Test to measure expiratory airflow and volume162$5,199$25
Test to measure the level of nitric oxide gas153$3,583$18
New patient visit (60+ min)16$3,099$194
New patient visit (30+ min)17$1,616$95
Test for allergy using allergenic extract injected into skin25$1,026$8

Who their Medicare patients are

287 Original Medicare patients in 2024. Average age 74 · Women 67% · Health risk score 0.89. At or below the middle of the specialty; the typical allergy/ immunology clinician is at 1.

Conditions among them: High blood pressure 64% · Diabetes 22% · Coronary heart disease 19% · Atrial fibrillation 16% · Depression 16% · COPD 15% · Cancer 14% · Chronic kidney disease 11% · Heart failure 8% · Stroke 8%.

The office billed $340,652, Medicare allowed $99,150 and paid $73,771; for 4,592 services of 24 kinds.

Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.

Year by year

Original Medicare by year
20242874,592740.89$340,652$73,771
20232774,237730.80$316,020$67,369
20222373,665730.85$244,314$54,487
20212433,555730.84$208,710$62,656
20202272,593730.84$124,221$44,863
20192824,681730.86$174,185$69,751
20182423,160720.84$134,220$50,243
20172544,242720.82$154,361$60,729
20161938,045720.86$329,757$173,422
20151946,791710.75$290,262$143,601
20141786,208710.82$215,664$100,787
20131502,610710.85$107,172$48,394

Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.

See the services billed each year

2023: 13 services

Original Medicare services billed in 2023
Professional service for preparation and provision of 1 or more antigens46$12,267$14
Short return visit (20+ min)131$10,887$70
Return visit (30+ min)83$9,901$99
Professional service for multiple injections of allergen50$5,635$10
New patient visit (45+ min)42$5,544$132
Test to measure expiratory airflow and volume164$4,925$22
Test for allergy using allergenic extract29$4,617$3
Test to measure the level of nitric oxide gas155$3,469$16
Long return visit (40+ min)18$3,179$144
New patient visit (60+ min)11$1,983$180
New patient visit (30+ min)13$1,102$85
Test for allergy using allergenic extract injected into skin19$759$7
Short return visit13$646$50

2022: 10 services

Original Medicare services billed in 2022
Professional service for preparation and provision of 1 or more antigens42$10,645$14
Return visit (30+ min)86$9,852$103
Short return visit (20+ min)101$6,897$63
Professional service for multiple injections of allergen52$5,360$9
New patient visit (45+ min)37$5,053$137
Test for allergy using allergenic extract23$4,454$3
Test to measure expiratory airflow and volume123$3,436$23
Test to measure the level of nitric oxide gas108$2,217$17
Long return visit (40+ min)13$2,201$129
Test for allergy using allergenic extract injected into skin13$473$8

2021: 10 services

Original Medicare services billed in 2021
Short return visit (20+ min)137$12,214$74
Professional service for preparation and provision of 1 or more antigens41$11,486$15
Return visit (30+ min)81$10,383$112
Professional service for multiple injections of allergen46$5,456$10
Test for allergy using allergenic extract19$4,968$4
New patient visit (45+ min)32$4,715$147
Test to measure expiratory airflow and volume91$3,352$29
Test to measure the level of nitric oxide gas78$2,000$20
New patient visit (60+ min)11$1,848$168
Test for allergy using allergenic extract injected into skin11$547$9

2020: 8 services

Original Medicare services billed in 2020
Professional service for preparation and provision of 1 or more antigens41$9,020$14
Short return visit (20+ min)138$8,239$50
Return visit (30+ min)70$7,122$88
Professional service for multiple injections of allergen51$5,709$9
New patient visit (45+ min)36$4,756$132
Test for allergy using allergenic extract14$2,825$4
Test to measure expiratory airflow and volume67$2,114$26
Test to measure the level of nitric oxide gas47$925$16

2019: 9 services

Original Medicare services billed in 2019
Short return visit (20+ min)192$15,209$60
Test for allergy using allergenic extract36$9,221$4
Professional service for preparation and provision of 1 or more antigens43$9,195$13
Test to measure expiratory airflow and volume165$7,622$32
New patient visit (45+ min)56$7,305$130
Return visit (30+ min)60$6,296$90
Professional service for multiple injections of allergen47$4,861$9
Test to measure the level of nitric oxide gas102$2,423$19
Test for allergy using allergenic extract injected into skin20$962$8

2018: 8 services

Original Medicare services billed in 2018
Short return visit (20+ min)161$12,602$55
Test to measure expiratory airflow and volume143$6,431$30
Professional service for preparation and provision of 1 or more antigens38$5,881$11
Test for allergy using allergenic extract20$5,666$5
New patient visit (45+ min)44$5,291$120
Return visit (30+ min)48$4,967$83
Professional service for multiple injections of allergen48$3,961$8
Test to measure the level of nitric oxide gas83$1,901$18

2017: 9 services

Original Medicare services billed in 2017
Test for allergy using allergenic extract37$12,913$6
Short return visit (20+ min)159$12,313$58
Professional service for preparation and provision of 1 or more antigens37$7,806$11
Test to measure expiratory airflow and volume159$6,839$30
New patient visit (45+ min)53$6,163$116
Return visit (30+ min)57$4,697$75
Professional service for multiple injections of allergen37$3,736$9
Test to measure the level of nitric oxide gas112$2,432$16
Test for allergy using allergenic extract injected into skin24$1,029$7

2016: 9 services

Original Medicare services billed in 2016
Short return visit (20+ min)135$10,395$56
Test for allergy using allergenic extract24$10,177$6
Professional service for preparation and provision of 1 or more antigens30$7,763$12
Test to measure expiratory airflow and volume123$7,094$31
New patient visit (45+ min)42$5,699$136
Return visit (30+ min)37$3,450$77
Professional service for multiple injections of allergen30$3,050$8
Test to measure the level of nitric oxide gas92$2,141$17
Test for allergy using allergenic extract injected into skin13$691$7

2015: 9 services

Original Medicare services billed in 2015
Short return visit (20+ min)127$9,791$57
Professional service for preparation and provision of 1 or more antigens34$7,747$11
Test to measure expiratory airflow and volume118$6,695$33
Return visit (30+ min)54$5,706$82
Test for allergy using allergenic extract14$5,632$6
New patient visit (45+ min)30$4,163$139
Professional service for multiple injections of allergen33$3,656$9
Test to measure the level of nitric oxide gas93$2,406$19
Test for allergy using allergenic extract injected into skin11$587$7

2014: 10 services

Original Medicare services billed in 2014
Test for allergy using allergenic extract31$14,837$6
Short return visit (20+ min)115$9,164$58
Professional service for preparation and provision of 1 or more antigens31$8,072$12
Test to measure expiratory airflow and volume107$5,441$33
Professional service for multiple injections of allergen31$4,387$9
New patient visit (45+ min)30$4,317$144
Return visit (30+ min)34$3,272$86
Test to measure the level of nitric oxide gas71$1,673$18
New patient visit (30+ min)19$1,256$66
Test for allergy using allergenic extract injected into skin18$832$7

2013: 9 services

Original Medicare services billed in 2013
Professional service for preparation and provision of 1 or more antigens28$8,440$12
Short return visit (20+ min)97$6,868$58
Test for allergy using allergenic extract13$5,350$6
Test to measure expiratory airflow and volume92$4,643$34
Return visit (30+ min)38$3,876$84
Professional service for multiple injections of allergen31$3,788$10
New patient visit (45+ min)13$1,733$133
Test to measure the level of nitric oxide gas59$1,435$19
New patient visit (30+ min)14$1,240$89

Drugs they prescribed that Part D paid

$1,674,857

Pharmacies billed $1,674,857 in 2024.

This is pharmacy cost, not the office bill, and not what patients paid.

Opioids were 0% of their Part D prescriptions (0 of 1,450) in 2024. At or below the middle of the specialty; the typical allergy/ immunology clinician is at 0%.

824 generic and 626 brand-name prescriptions · $1,674,857 in drug cost · 36 antibiotic prescriptions to 29 people.

Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.

Largest Part D drug costs
DupixentNone39$154,782$3,969
HizentraImmune globulin14$146,113$10,437
Trelegy ElliptaNone111$111,300$1,003
DupixentNone26$98,257$3,779
XolairNone22$76,196$3,463
See all 31 drugs
Every Part D drug this clinician prescribed
DupixentNone39$154,782$3,969
HizentraImmune globulin14$146,113$10,437
Trelegy ElliptaNone111$111,300$1,003
DupixentNone26$98,257$3,779
XolairNone22$76,196$3,463
NucalaNone13$49,310$3,793
DuleraNone46$22,591$491
Breo ElliptaNone41$21,332$520
AzelastineNone150$7,522$50
Advair HfaNone16$7,105$444
Arnuity ElliptaNone13$6,436$495
Fluticasone-SalmeterolNone24$5,284$220
Advair DiskusNone14$5,283$377
IpratropiumNone93$4,369$47
Pulmicort FlexhalerNone13$4,336$334
RyaltrisNone17$4,089$241
Albuterol Sulfate HfaNone92$3,580$39
MontelukastNone266$2,993$11
Wixela InhubNone22$2,683$122
BreynaNone12$2,570$214
Levalbuterol Tartrate HfaNone24$2,557$107
EpinephrineNone13$1,115$86
Ventolin HfaNone15$829$55
Fluticasone PropionateNone21$570$27
OmeprazoleNone12$343$29
Lidocaine-PrilocaineNone22$331$15
ClarithromycinNone12$229$19
HydroxyzineNone11$219$20
Amoxicillin-Clavulanate PotassNone18$205$11
PrednisoneNone33$202$6
MupirocinNone14$105$7

Year by year

Part D prescribing by year
20241,4502540% (0)43%$1,674,857
20231,4892590% (0)42%$1,609,019
20221,2972460% (0)41%$1,106,341
20211,1972220% (0)39%$931,442
20201,3382460% (0)None$584,097
20191,3532580% (0)None$782,877
20181,3042390% (0)42%$877,734
20171,2592230% (0)41%$1,006,518
20161,0101520% (0)42%$1,087,373
20151,0101670% (0)41%$744,440
2014978145None47%$361,160
20138071080% (0)52%$124,597

Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.

See the drugs prescribed each year

2023: 27 drugs

Part D drugs prescribed in 2023
DupixentNone33$131,054$3,971
HizentraImmune globulin13$99,108$7,624
Trelegy ElliptaNone93$97,166$1,045
DupixentNone25$89,488$3,580
XolairNone22$61,263$2,785
NucalaNone13$47,284$3,637
Advair DiskusNone35$27,759$793
DuleraNone33$22,543$683
Breo ElliptaNone38$21,305$561
SymbicortNone37$19,699$532
Flovent HfaNone28$16,421$586
Advair HfaNone20$13,060$653
AzelastineNone166$10,782$65
Pulmicort FlexhalerNone16$5,092$318
MontelukastNone284$4,805$17
RyaltrisNone15$4,331$289
Albuterol Sulfate HfaNone93$4,179$45
Wixela InhubNone11$3,630$330
IpratropiumNone71$3,278$46
Levalbuterol Tartrate HfaNone17$1,717$101
Ventolin HfaNone17$1,435$84
Fluticasone PropionateNone38$1,231$32
Mometasone FuroateNone15$1,000$67
HydroxyzineNone12$773$64
PrednisoneNone33$176$5
Paxlovid (Eua)None16$153$10
OmeprazoleNone13$139$11

2022: 26 drugs

Part D drugs prescribed in 2022
Dupixent20$67,790$3,389
Dupixent18$66,254$3,681
Xolair24$61,929$2,580
Nucala14$46,177$3,298
Trelegy Ellipta46$44,991$978
Symbicort43$30,719$714
Breo Ellipta40$25,149$629
Advair Diskus37$24,509$662
Dulera43$22,288$518
Flovent Hfa35$20,999$600
Alvesco13$18,511$1,424
Advair Hfa19$13,339$702
Azelastine170$11,139$66
Wixela Inhub17$7,038$414
Montelukast253$4,408$17
Ipratropium65$3,544$55
Epinephrine12$3,538$295
Azelastine-Fluticasone13$3,422$263
Albuterol Sulfate Hfa55$3,216$58
Mometasone Furoate23$2,201$96
Levalbuterol Tartrate Hfa20$1,476$74
Fluticasone Propionate32$1,035$32
Omeprazole12$299$25
Amoxicillin-Clavulanate Potass11$142$13
Paxlovid (Eua)12$124$10
Prednisone29$118$4

2021: 26 drugs

Part D drugs prescribed in 2021
Dupixent33$122,230$3,704
Nucala14$47,552$3,397
Symbicort39$30,999$795
Xolair13$29,942$2,303
Dulera52$25,299$487
Flovent Hfa35$20,757$593
Advair Diskus29$20,459$705
Breo Ellipta31$17,832$575
Trelegy Ellipta14$13,904$993
Alvesco12$13,550$1,129
Wixela Inhub43$11,854$276
Azelastine195$10,087$52
Advair Hfa11$7,288$663
Montelukast231$3,845$17
Ipratropium60$3,831$64
Mometasone Furoate19$3,829$202
Albuterol Sulfate Hfa56$3,823$68
Arnuity Ellipta13$3,418$263
Zetonna13$2,991$230
Epinephrine11$2,688$244
Azelastine-Fluticasone12$2,454$205
Levalbuterol Tartrate Hfa17$1,295$76
Fluticasone Propionate28$696$25
Hydroxyzine15$298$20
Omeprazole15$289$19
Prednisone11$68$6

2020: 28 drugs

Part D drugs prescribed in 2020
Dupixent17$66,315$3,901
Xolair23$40,977$1,782
Symbicort53$39,703$749
Dulera59$30,344$514
Advair Diskus36$28,661$796
Flovent Hfa35$24,276$694
Breo Ellipta21$11,899$567
Advair Hfa23$11,728$510
Azelastine183$11,219$61
Alvesco13$10,668$821
Spiriva Respimat11$8,558$778
Wixela Inhub24$7,193$300
Atrovent Hfa14$6,103$436
Ipratropium78$5,930$76
Bevespi Aerosphere14$5,290$378
Montelukast280$5,042$18
Arnuity Ellipta14$4,941$353
Albuterol Sulfate Hfa70$4,835$69
Azelastine-Fluticasone13$4,606$354
Mometasone Furoate24$3,300$137
Zetonna14$3,136$224
Ventolin Hfa19$1,441$76
Fluticasone Propionate39$1,398$36
Clarithromycin18$809$45
Omeprazole11$326$30
Olopatadine11$302$27
Amoxicillin-Clavulanate Potass13$141$11
Prednisone24$104$4

2019: 27 drugs

Part D drugs prescribed in 2019
Dupixent11$34,763$3,160
Symbicort57$33,663$591
Alvesco22$26,631$1,210
Dulera55$23,272$423
Flovent Hfa32$21,651$677
Xolair12$21,386$1,782
Advair Diskus35$20,167$576
Breo Ellipta31$12,040$388
Azelastine148$10,100$68
Advair Hfa22$9,822$446
Wixela Inhub16$6,810$426
Bevespi Aerosphere18$6,513$362
Montelukast286$5,471$19
Proair Hfa40$4,839$121
Arnuity Ellipta16$4,376$273
Ipratropium73$4,030$55
Asmanex Hfa16$3,472$217
Mometasone Furoate12$3,411$284
Ventolin Hfa34$2,452$72
Clarithromycin38$1,757$46
Olopatadine23$1,659$72
Albuterol Sulfate Hfa21$1,449$69
Fluticasone Propionate49$1,374$28
Omeprazole11$402$37
Prednisone44$213$5
Hydroxyzine13$97$7
Mupirocin11$96$9

2018: 23 drugs

Part D drugs prescribed in 2018
Advair Diskus39$32,693$838
Alvesco37$26,135$706
Symbicort45$25,353$563
Flovent Hfa51$23,941$469
Breo Ellipta32$17,430$545
Dulera35$15,221$435
Azelastine159$11,868$75
Advair Hfa26$11,105$427
Spiriva Respimat22$10,061$457
Zetonna20$5,264$263
Mometasone Furoate19$5,086$268
Flovent Diskus11$5,057$460
Montelukast278$4,895$18
Incruse Ellipta12$4,779$398
Proair Hfa43$4,130$96
Ipratropium68$3,568$52
Dymista14$2,722$194
Olopatadine13$2,565$197
Ventolin Hfa30$1,917$64
Fluticasone Propionate41$1,229$30
Clarithromycin25$1,206$48
Hydroxyzine31$713$23
Prednisone29$291$10

2017: 23 drugs

Part D drugs prescribed in 2017
Alvesco49$22,541$460
Dulera37$20,670$559
Advair Diskus38$20,645$543
Symbicort41$17,009$415
Flovent Hfa31$14,550$469
Azelastine142$9,910$70
Advair Hfa22$8,755$398
Breo Ellipta12$7,002$584
Incruse Ellipta12$6,972$581
Atrovent Hfa11$6,094$554
Flovent Diskus15$4,831$322
Ipratropium70$4,403$63
Asmanex Hfa18$4,316$240
Montelukast236$4,253$18
Proair Hfa43$3,928$91
Zetonna11$3,491$317
Mometasone Furoate12$2,820$235
Ventolin Hfa36$2,024$56
Fluticasone Propionate62$1,768$29
Clarithromycin33$1,346$41
Hydroxyzine39$843$22
Prednisone42$299$7
Amoxicillin-Clavulanate Potass13$209$16

2016: 23 drugs

Part D drugs prescribed in 2016
Nucala11$30,186$2,744
Dulera48$16,847$351
Alvesco41$16,092$392
Flovent Hfa29$13,206$455
Advair Diskus24$11,982$499
Symbicort22$10,351$470
Azelastine105$8,175$78
Spiriva15$7,984$532
Spiriva Respimat20$6,714$336
Montelukast216$4,810$22
Advair Hfa14$4,763$340
Nasonex17$4,500$265
Incruse Ellipta11$4,073$370
Atrovent Hfa13$3,846$296
Proair Hfa35$3,055$87
Ipratropium51$2,806$55
Fluticasone Propionate79$1,988$25
Hydroxyzine19$975$51
Ventolin Hfa14$830$59
Clarithromycin16$598$37
Prednisone17$134$8
Azithromycin11$112$10
Pantoprazole11$48$4

2015: 21 drugs

Part D drugs prescribed in 2015
Advair Diskus53$28,604$540
Spiriva34$14,649$431
Alvesco27$12,853$476
Symbicort24$8,861$369
Azelastine79$7,029$89
Dulera24$6,750$281
Advair Hfa18$6,513$362
Flovent Hfa16$6,102$381
Montelukast212$4,852$23
Nasonex18$4,662$259
Spiriva Respimat12$3,704$309
Proair Hfa35$3,688$105
Atrovent Hfa14$3,680$263
Dymista17$3,416$201
Asmanex11$2,691$245
Ipratropium73$2,570$35
Clarithromycin24$1,749$73
Fluticasone Propionate83$1,603$19
Hydroxyzine14$804$57
Amoxicillin-Clavulanate Potass17$354$21
Omeprazole11$200$18

2014: 19 drugs

Part D drugs prescribed in 2014
Gamunex-CImmune globulin24$37,802$1,575
Advair DiskusNone82$33,516$409
SpirivaNone43$16,252$378
NasonexNone38$11,613$306
SymbicortNone26$10,000$385
AlvescoNone21$8,403$400
Advair HfaNone18$6,984$388
MontelukastNone176$6,764$38
AzelastineNone62$6,252$101
DuleraNone17$5,553$327
PatanolNone12$3,632$303
Flovent HfaNone12$3,631$303
Proair HfaNone38$3,367$89
Fluticasone PropionateNone100$3,083$31
IpratropiumNone68$2,441$36
ClarithromycinNone25$1,487$59
Ventolin HfaNone12$923$77
Levocetirizine DihydrochlorideNone13$557$43
PantoprazoleNone22$176$8

2013: 18 drugs

Part D drugs prescribed in 2013
Advair Diskus80$26,856$336
Spiriva48$18,035$376
Nasonex54$13,324$247
Dulera24$7,638$318
Montelukast117$5,952$51
Flovent Hfa19$5,632$296
Alvesco21$4,558$217
Azelastine51$3,781$74
Proair Hfa35$3,094$88
Nexium14$3,043$217
Patanol12$2,856$238
Fluticasone Propionate55$2,403$44
Ipratropium43$1,292$30
Clarithromycin14$1,156$83
Levocetirizine Dihydrochloride27$860$32
Hydroxyzine16$586$37
Azithromycin13$137$11
Pantoprazole14$106$8

Money from drug and device companies

$3,936 in 2025

Industry payments by year
20251339None$3,936
20241021$1,513$2,119
20231158$1,300$2,931
20221254$11,200$12,014
20211552$17,700$18,447
20201451$5,550$6,621
20191986$16,761$20,371

Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.

A payment is not proof that care is biased.

Payments by company
AstraZeneca Pharmaceuticals LPFasenra$3,027
12 payments
  • Meals for Fasenra · 2025-12-03 · $4
  • Meals for Fasenra · 2025-12-03 · $17
  • Meals for Tezspire · 2025-09-03 · $24
  • Meals for Fasenra · 2025-05-07 · $125
  • Travel · 2025-04-25 · $700
  • Travel · 2025-04-25 · $2,000
  • Meals for Fasenra · 2025-04-21 · $20
  • Meals for Airsupra · 2025-03-19 · $30
  • Travel · 2025-01-29 · $17
  • Meals · 2025-01-29 · $24
  • Travel · 2025-01-29 · $48
  • Meals for Fasenra · 2025-01-21 · $17
GlaxoSmithKlineNucala$272
6 payments
  • Meals · 2025-11-19 · $125
  • Meals for Trelegy Ellipta · 2025-10-21 · $13
  • Meals for Nucala · 2025-08-27 · $25
  • Meals for Nucala · 2025-06-23 · $2
  • Meals for Trelegy Ellipta · 2025-05-29 · $14
  • Meals · 2025-03-02 · $93
ARS Pharmaceuticals OperationsNeffy$173
5 payments
  • Meals for Neffy · 2025-10-30 · $3
  • Meals for Neffy · 2025-09-10 · $17
  • Meals for Neffy · 2025-07-21 · $9
  • Meals for Neffy · 2025-04-30 · $19
  • Meals for Neffy · 2025-04-01 · $125
Ionis PharmaceuticalsDawnzera$143
2 payments
  • Meals for Dawnzera · 2025-11-11 · $124
  • Meals for Dawnzera · 2025-10-07 · $20
CSL BehringHizentra$117
5 payments
  • Meals for Andembry · 2025-11-10 · $20
  • Meals for Hizentra · 2025-10-15 · $39
  • Meals for Andembry · 2025-07-22 · $21
  • Meals for Hizentra · 2025-05-14 · $21
  • Meals for Haegarda · 2025-04-15 · $16
AmgenTezspire$33
1 payment
  • Meals for Tezspire · 2025-02-27 · $33
See all 39 published payments
Every published payment
AstraZeneca Pharmaceuticals LPMeals · 2025-12-03Fasenra$4
AstraZeneca Pharmaceuticals LPMeals · 2025-12-03Fasenra$17
GlaxoSmithKlineMeals · 2025-11-19None$125
Ionis PharmaceuticalsMeals · 2025-11-11Dawnzera$124
CSL BehringMeals · 2025-11-10Andembry$20
Pharming HealthcareMeals · 2025-11-05Ruconest$20
GenzymeMeals · 2025-11-05Dupixent$13
ARS Pharmaceuticals OperationsMeals · 2025-10-30Neffy$3
Grifols USAMeals · 2025-10-22Xembify$15
GlaxoSmithKlineMeals · 2025-10-21Trelegy Ellipta$13
CSL BehringMeals · 2025-10-15Hizentra$39
Ionis PharmaceuticalsMeals · 2025-10-07Dawnzera$20
GenzymeMeals · 2025-10-02Dupixent$16
Galderma Laboratories L.P.Meals · 2025-10-02Nemluvio$31
ARS Pharmaceuticals OperationsMeals · 2025-09-10Neffy$17
AstraZeneca Pharmaceuticals LPMeals · 2025-09-03Tezspire$24
GlaxoSmithKlineMeals · 2025-08-27Nucala$25
BioCryst US Sales Co.Meals · 2025-08-06Orladeyo$30
CSL BehringMeals · 2025-07-22Andembry$21
ARS Pharmaceuticals OperationsMeals · 2025-07-21Neffy$9
Octapharma USAMeals · 2025-07-16Cutaquig$27
GlaxoSmithKlineMeals · 2025-06-23Nucala$2
GlaxoSmithKlineMeals · 2025-05-29Trelegy Ellipta$14
CSL BehringMeals · 2025-05-14Hizentra$21
AstraZeneca Pharmaceuticals LPMeals · 2025-05-07Fasenra$125
ARS Pharmaceuticals OperationsMeals · 2025-04-30Neffy$19
AstraZeneca Pharmaceuticals LPTravel · 2025-04-25None$700
AstraZeneca Pharmaceuticals LPTravel · 2025-04-25None$2,000
AstraZeneca Pharmaceuticals LPMeals · 2025-04-21Fasenra$20
CSL BehringMeals · 2025-04-15Haegarda$16
ARS Pharmaceuticals OperationsMeals · 2025-04-01Neffy$125
Teva Pharmaceuticals USAMeals · 2025-03-31Albuterol Sulfate$19
AstraZeneca Pharmaceuticals LPMeals · 2025-03-19Airsupra$30
GlaxoSmithKlineMeals · 2025-03-02None$93
AmgenMeals · 2025-02-27Tezspire$33
AstraZeneca Pharmaceuticals LPTravel · 2025-01-29None$17
AstraZeneca Pharmaceuticals LPMeals · 2025-01-29None$24
AstraZeneca Pharmaceuticals LPTravel · 2025-01-29None$48
AstraZeneca Pharmaceuticals LPMeals · 2025-01-21Fasenra$17
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)

2024: $2,119

Payments by company in 2024
Takeda Pharmaceuticals U.S.A.None$1,513
1 payment
  • Consulting · 2024-07-19 · $1,513
AstraZeneca Pharmaceuticals LPFasenra$144
7 payments
  • Meals for Fasenra · 2024-10-16 · $16
  • Meals for Tezspire · 2024-09-18 · $23
  • Meals for Fasenra · 2024-05-14 · $18
  • Meals for Tezspire · 2024-04-24 · $22
  • Meals for Airsupra · 2024-04-04 · $18
  • Meals for Fasenra · 2024-03-14 · $23
  • Meals for Fasenra · 2024-02-28 · $23
Genentech USAXolair$122
1 payment
  • Meals for Xolair · 2024-06-12 · $122
Pharming HealthcareRuconest$80
3 payments
  • Meals for Ruconest · 2024-12-12 · $27
  • Meals for Ruconest · 2024-08-14 · $38
  • Meals for Ruconest · 2024-03-20 · $15
CSL BehringHaegarda$79
3 payments
  • Meals for Haegarda · 2024-11-21 · $25
  • Meals for Haegarda · 2024-08-08 · $28
  • Meals for Hizentra · 2024-01-24 · $25
Regeneron Healthcare SolutionsDupixent$55
2 payments
  • Meals for Dupixent · 2024-12-04 · $26
  • Meals for Dupixent · 2024-04-18 · $29
Blueprint MedicinesAyvakit$42
1 payment
  • Meals for Ayvakit · 2024-03-27 · $42
Octapharma USACutaquig$37
1 payment
  • Meals for Cutaquig · 2024-07-10 · $37
AmgenActimmune$34
1 payment
  • Meals for Actimmune · 2024-02-22 · $34
GlaxoSmithKlineNucala$14
1 payment
  • Meals for Nucala · 2024-01-31 · $14

2023: $2,931

Payments by company in 2023
GlaxoSmithKlineNucala$1,610
15 payments
  • Meals for Nucala · 2023-11-16 · $13
  • Meals for Nucala · 2023-10-16 · $23
  • Meals for Nucala · 2023-09-21 · $32
  • Meals for Nucala · 2023-08-21 · $12
  • Meals for Nucala · 2023-07-31 · $24
  • Meals for Nucala · 2023-07-25 · $9
  • Meals for Trelegy Ellipta · 2023-06-22 · $18
  • Meals for Trelegy Ellipta · 2023-06-20 · $9
  • Meals for Trelegy Ellipta · 2023-05-25 · $8
  • Meals for Nucala · 2023-05-04 · $124
  • Meals for Nucala · 2023-04-07 · $8
  • Meals for Trelegy Ellipta · 2023-02-24 · $14
  • Meals for Trelegy Ellipta · 2023-02-03 · $9
  • Paid to speak or teach · 2023-02-01 · $1,300
  • Meals for Nucala · 2023-01-26 · $9
AstraZeneca Pharmaceuticals LPTezspire$402
15 payments
  • Meals for Airsupra · 2023-12-13 · $14
  • Meals for Fasenra · 2023-11-09 · $18
  • Meals for Airsupra · 2023-10-25 · $35
  • Meals for Fasenra · 2023-10-03 · $16
  • Meals for Breztri · 2023-09-06 · $18
  • Meals for Tezspire · 2023-08-24 · $26
  • Meals for Fasenra · 2023-08-08 · $17
  • Meals for Tezspire · 2023-07-27 · $15
  • Meals for Tezspire · 2023-07-19 · $20
  • Meals for Fasenra · 2023-05-09 · $16
  • Meals for Tezspire · 2023-05-03 · $20
  • Meals for Tezspire · 2023-04-06 · $124
  • Meals for Fasenra · 2023-03-29 · $16
  • Meals for Fasenra · 2023-01-18 · $16
  • Meals for Tezspire · 2023-01-12 · $31
CSL BehringHizentra$393
12 payments
  • Education for Hizentra · 2023-12-01 · $60
  • Education for Hizentra · 2023-11-21 · $60
  • Education for Hizentra · 2023-11-21 · $60
  • Education for Hizentra · 2023-11-21 · $60
  • Meals for Hizentra · 2023-10-30 · $35
  • Meals for Hizentra · 2023-09-06 · $9
  • Meals for Hizentra · 2023-08-28 · $36
  • Meals for Hizentra · 2023-08-17 · $9
  • Meals for Hizentra · 2023-07-07 · $25
  • Meals for Hizentra · 2023-06-15 · $16
  • Meals for Hizentra · 2023-05-03 · $2
  • Meals for Hizentra · 2023-03-14 · $22
GenzymeDupixent$185
3 payments
  • Meals for Dupixent · 2023-08-24 · $18
  • Meals for Dupixent · 2023-06-01 · $149
  • Meals for Dupixent · 2023-05-31 · $18
Merck Sharp & DohmeNone$157
1 payment
  • Meals · 2023-02-25 · $157
Grifols USAXembify$46
2 payments
  • Meals for Xembify · 2023-07-21 · $23
  • Meals for Xembify · 2023-02-22 · $22
Octapharma USACutaquig$45
2 payments
  • Meals for Cutaquig · 2023-11-02 · $21
  • Meals for Cutaquig · 2023-09-14 · $24
Genentech USAXolair$32
1 payment
  • Meals for Xolair · 2023-03-01 · $32
ALK-AbelloOdactra$24
1 payment
  • Meals for Odactra · 2023-03-23 · $24
HospiraOctagam Immune Globulin (Human)$23
1 payment
  • Meals for Octagam Immune Globulin (Human) · 2023-04-27 · $23
Hikma Pharmaceuticals USARyaltris$14
1 payment
  • Meals for Ryaltris · 2023-12-19 · $14

2022: $12,014

Payments by company in 2022
GlaxoSmithKlineTrelegy Ellipta$9,414
21 payments
  • Meals for Trelegy Ellipta · 2022-12-22 · $4
  • Meals for Nucala · 2022-12-16 · $11
  • Meals for Trelegy Ellipta · 2022-12-15 · $5
  • Meals for Nucala · 2022-10-19 · $10
  • Meals for Trelegy Ellipta · 2022-10-12 · $5
  • Paid to speak or teach · 2022-09-28 · $1,300
  • Meals for Trelegy Ellipta · 2022-09-21 · $9
  • Meals for Nucala · 2022-09-03 · $10
  • Paid to speak or teach for Trelegy Ellipta · 2022-08-03 · $3,900
  • Meals for Nucala · 2022-07-29 · $3
  • Meals for Nucala · 2022-07-28 · $30
  • Meals for Trelegy Ellipta · 2022-07-12 · $121
  • Meals for Nucala · 2022-06-17 · $33
  • Meals for Trelegy Ellipta · 2022-06-14 · $9
  • Paid to speak or teach for Trelegy Ellipta · 2022-06-08 · $1,300
  • Paid to speak or teach for Trelegy Ellipta · 2022-05-04 · $1,300
  • Meals for Nucala · 2022-04-28 · $33
  • Meals for Trelegy Ellipta · 2022-04-12 · $6
  • Meals for Nucala · 2022-04-07 · $10
  • Paid to speak or teach for Trelegy Ellipta · 2022-03-30 · $1,300
  • Meals for Nucala · 2022-01-20 · $14
OptiNose USXhance$2,114
5 payments
  • Meals for Xhance · 2022-11-11 · $5
  • Meals for Xhance · 2022-11-04 · $4
  • Meals for Xhance · 2022-11-04 · $4
  • Paid to speak or teach for Xhance · 2022-08-25 · $1,100
  • Paid to speak or teach for Xhance · 2022-04-01 · $1,000
AstraZeneca Pharmaceuticals LPTezspire$217
10 payments
  • Meals · 2022-11-11 · $13
  • Meals for Breztri · 2022-10-26 · $17
  • Meals for Tezspire · 2022-09-16 · $16
  • Meals for Tezspire · 2022-08-10 · $16
  • Meals for Fasenra · 2022-05-11 · $17
  • Meals for Tezspire · 2022-04-14 · $69
  • Meals for Tezspire · 2022-04-07 · $23
  • Meals for Fasenra · 2022-03-30 · $15
  • Meals for Breztri · 2022-03-23 · $16
  • Meals for Fasenra · 2022-01-05 · $16
GenzymeDupixent$117
1 payment
  • Meals for Dupixent · 2022-10-03 · $117
Boehringer Ingelheim PharmaceuticalsStiolto Respimat$32
2 payments
  • Meals for Stiolto Respimat · 2022-06-08 · $15
  • Meals for Stiolto Respimat · 2022-04-20 · $16
Novartis PharmaceuticalsXolair$24
1 payment
  • Meals for Xolair · 2022-08-24 · $24
ALK-AbelloOdactra$20
1 payment
  • Meals for Odactra · 2022-09-29 · $20
Teva Pharmaceuticals USAAirduo Digihaler$19
1 payment
  • Meals for Airduo Digihaler · 2022-11-30 · $19
CSL BehringHizentra$15
1 payment
  • Meals for Hizentra · 2022-03-08 · $15
Genentech USAXolair$15
1 payment
  • Meals for Xolair · 2022-03-16 · $15
Hikma Pharmaceuticals USAKloxxado$14
1 payment
  • Meals for Kloxxado · 2022-11-18 · $14
Takeda Pharmaceuticals U.S.A.Takhzyro$13
1 payment
  • Meals for Takhzyro · 2022-04-28 · $13

2021: $18,447

Payments by company in 2021
GlaxoSmithKlineTrelegy Ellipta$13,463
23 payments
  • Paid to speak or teach for Trelegy Ellipta · 2021-12-21 · $600
  • Meals for Nucala · 2021-12-06 · $14
  • Paid to speak or teach for Trelegy Ellipta · 2021-11-10 · $1,200
  • Paid to speak or teach for Trelegy Ellipta · 2021-11-10 · $1,200
  • Meals for Nucala · 2021-10-25 · $8
  • Meals for Trelegy Ellipta · 2021-09-30 · $24
  • Paid to speak or teach for Trelegy Ellipta · 2021-09-29 · $1,200
  • Paid to speak or teach for Trelegy Ellipta · 2021-09-15 · $3,600
  • Meals for Nucala · 2021-08-27 · $13
  • Meals for Nucala · 2021-08-05 · $19
  • Paid to speak or teach for Trelegy Ellipta · 2021-08-05 · $1,200
  • Paid to speak or teach for Trelegy Ellipta · 2021-07-22 · $1,800
  • Meals for Trelegy Ellipta · 2021-07-01 · $26
  • Meals for Trelegy Ellipta · 2021-07-01 · $5
  • Meals for Nucala · 2021-05-27 · $34
  • Paid to speak or teach for Trelegy Ellipta · 2021-05-13 · $1,200
  • Meals for Nucala · 2021-04-21 · $21
  • Meals for Trelegy Ellipta · 2021-04-01 · $28
  • Paid to speak or teach for Trelegy Ellipta · 2021-04-01 · $1,200
  • Meals for Nucala · 2021-03-24 · $19
  • Meals for Trelegy Ellipta · 2021-01-28 · $21
  • Meals for Trelegy Ellipta · 2021-01-28 · $4
  • Meals for Nucala · 2021-01-27 · $28
Optinose USXhance$2,750
2 payments
  • Consulting for Xhance · 2021-03-04 · $2,000
  • Paid to speak or teach for Xhance · 2021-02-25 · $750
Merck Sharp & DohmeNone$1,000
1 payment
  • Consulting · 2021-04-21 · $1,000
Octapharma USACutaquig$750
1 payment
  • Honoraria for Cutaquig · 2021-04-24 · $750
AstraZeneca Pharmaceuticals LPFasenra$138
9 payments
  • Meals for Fasenra · 2021-12-07 · $17
  • Meals · 2021-11-10 · $20
  • Meals for Fasenra · 2021-10-14 · $15
  • Meals for Fasenra · 2021-08-05 · $16
  • Meals for Breztri · 2021-06-03 · $16
  • Meals for Fasenra · 2021-05-13 · $14
  • Meals for Breztri · 2021-03-18 · $14
  • Meals for Breztri · 2021-03-16 · $10
  • Meals for Fasenra · 2021-02-18 · $15
kaleoAuvi-Q$92
1 payment
  • Meals for Auvi-Q · 2021-09-11 · $92
Boehringer Ingelheim PharmaceuticalsStiolto Respimat$88
5 payments
  • Meals for Stiolto Respimat · 2021-12-01 · $16
  • Meals for Stiolto Respimat · 2021-10-28 · $17
  • Meals for Spiriva Respimat · 2021-08-26 · $17
  • Meals for Stiolto Respimat · 2021-05-26 · $17
  • Meals for Spiriva Respimat · 2021-02-03 · $21
PfizerEucrisa$36
2 payments
  • Meals for Eucrisa · 2021-05-19 · $21
  • Meals for Eucrisa · 2021-02-24 · $15
Grifols USAXembify$26
1 payment
  • Meals for Xembify · 2021-04-07 · $26
Horizon Therapeutics plcActimmune$25
1 payment
  • Meals for Actimmune · 2021-03-03 · $25
Regeneron Healthcare SolutionsDupixent$25
1 payment
  • Meals for Dupixent · 2021-02-25 · $25
Genentech USAXolair$18
1 payment
  • Meals for Xolair · 2021-06-30 · $18
CSL BehringHizentra$13
1 payment
  • Meals for Hizentra · 2021-09-15 · $13
Takeda Pharmaceuticals U.S.A.Cuvitru$13
1 payment
  • Meals for Cuvitru · 2021-09-29 · $13
UswmSymjepi$12
1 payment
  • Meals for Symjepi · 2021-10-20 · $12

2020: $6,621

Payments by company in 2020
GlaxoSmithKlineTrelegy Ellipta$5,024
20 payments
  • Paid to speak or teach for Trelegy Ellipta · 2020-12-16 · $1,200
  • Paid to speak or teach for Trelegy Ellipta · 2020-11-19 · $1,200
  • Meals for Trelegy Ellipta · 2020-11-12 · $17
  • Meals for Trelegy Ellipta · 2020-10-29 · $20
  • Meals for Trelegy Ellipta · 2020-10-29 · $3
  • Meals for Nucala · 2020-10-20 · $6
  • Meals for Nucala · 2020-10-20 · $3
  • Paid to speak or teach for Trelegy Ellipta · 2020-10-15 · $2,400
  • Meals for Anoro Ellipta · 2020-10-07 · $24
  • Meals for Nucala · 2020-09-30 · $32
  • Meals for Anoro Ellipta · 2020-09-22 · $11
  • Meals for Trelegy Ellipta · 2020-09-18 · $4
  • Meals for Trelegy Ellipta · 2020-09-18 · $20
  • Meals for Anoro Ellipta · 2020-08-06 · $7
  • Meals for Anoro Ellipta · 2020-07-28 · $25
  • Meals for Nucala · 2020-07-14 · $5
  • Meals for Nucala · 2020-05-13 · $22
  • Meals for Nucala · 2020-03-06 · $5
  • Meals for Anoro Ellipta · 2020-02-13 · $8
  • Meals for Anoro Ellipta · 2020-01-09 · $14
Merck Sharp & DohmeNone$750
1 payment
  • Consulting · 2020-08-28 · $750
Octapharma USACutaquig$228
1 payment
  • Meals for Cutaquig · 2020-12-16 · $228
Sanofi-Aventis U.S.Dupixent$177
3 payments
  • Education · 2020-09-04 · $31
  • Meals for Dupixent · 2020-02-05 · $87
  • Meals for Dupixent · 2020-02-03 · $59
AstraZeneca Pharmaceuticals LPFasenra$153
12 payments
  • Meals for Fasenra · 2020-12-10 · $14
  • Meals for Breztri Aerosphere · 2020-11-12 · $15
  • Education for Breztri Aerosphere · 2020-10-12 · $12
  • Meals for Symbicort · 2020-08-06 · $14
  • Meals for Fasenra · 2020-07-23 · $14
  • Meals for Symbicort · 2020-06-11 · $14
  • Meals for Fasenra · 2020-05-14 · $14
  • Meals for Fasenra · 2020-03-05 · $13
  • Meals for Fasenra · 2020-03-04 · $1
  • Education for Fasenra · 2020-01-23 · $15
  • Meals · 2020-01-21 · $14
  • Meals for Symbicort · 2020-01-16 · $13
GenzymeDupixent$59
3 payments
  • Meals for Dupixent · 2020-10-28 · $18
  • Meals for Dupixent · 2020-06-24 · $17
  • Meals for Dupixent · 2020-01-29 · $24
OptiNose USXhance$46
2 payments
  • Meals for Xhance · 2020-08-13 · $24
  • Meals for Xhance · 2020-03-12 · $22
Novartis PharmaceuticalsXolair$43
2 payments
  • Meals for Xolair · 2020-02-12 · $23
  • Meals for Ilaris · 2020-01-08 · $20
PfizerEucrisa$33
2 payments
  • Meals for Eucrisa · 2020-11-04 · $17
  • Meals for Eucrisa · 2020-08-19 · $15
Grifols USAXembify$28
1 payment
  • Meals for Xembify · 2020-03-01 · $28
Circassia PharmaceuticalsNiox Vero$25
1 payment
  • Meals for Niox Vero · 2020-02-05 · $25
Takeda Pharmaceuticals U.S.A.Cuvitru$20
1 payment
  • Meals for Cuvitru · 2020-11-25 · $20
Covis Pharma GmbHAlvesco$20
1 payment
  • Meals for Alvesco · 2020-06-11 · $20
Boehringer Ingelheim PharmaceuticalsSpiriva Respimat$14
1 payment
  • Meals for Spiriva Respimat · 2020-07-08 · $14

2019: $20,371

Payments by company in 2019
OptiNose USXhance$12,211
25 payments
  • Meals for Xhance · 2019-11-08 · $31
  • Meals for Xhance · 2019-10-02 · $22
  • Paid to speak or teach for Xhance · 2019-10-02 · $1,750
  • Meals for Xhance · 2019-09-18 · $18
  • Paid to speak or teach for Xhance · 2019-09-18 · $1,750
  • Travel for Xhance · 2019-09-18 · $43
  • Meals for Xhance · 2019-09-03 · $22
  • Honoraria for Xhance · 2019-08-02 · $750
  • Meals for Xhance · 2019-08-02 · $24
  • Paid to speak or teach for Xhance · 2019-08-02 · $1,750
  • Meals for Xhance · 2019-08-02 · $16
  • Meals for Xhance · 2019-05-22 · $14
  • Honoraria for Xhance · 2019-04-11 · $2,250
  • Travel for Xhance · 2019-04-11 · $64
  • Meals for Xhance · 2019-03-28 · $104
  • Meals for Xhance · 2019-03-27 · $116
  • Honoraria for Xhance · 2019-03-11 · $1,750
  • Travel for Xhance · 2019-03-11 · $16
  • Meals for Xhance · 2019-03-07 · $22
  • Meals for Xhance · 2019-02-28 · $120
  • Meals for Xhance · 2019-02-27 · $128
  • Meals for Xhance · 2019-01-21 · $61
  • Meals for Xhance · 2019-01-12 · $68
  • Travel for Xhance · 2019-01-11 · $1,148
  • Meals for Xhance · 2019-01-11 · $173
Merck Sharp & DohmeMk-7264$4,689
2 payments
  • Meals for Asmanex · 2019-03-27 · $14
  • Consulting for Mk-7264 · 2019-01-02 · $4,675
Regeneron Healthcare SolutionsDupixent$1,318
3 payments
  • Meals for Dupixent · 2019-12-04 · $26
  • Meals for Dupixent · 2019-04-12 · $53
  • Consulting for Dupixent · 2019-02-06 · $1,240
AstraZeneca Pharmaceuticals LPFasenra$1,002
11 payments
  • Meals for Symbicort · 2019-11-14 · $13
  • Meals for Bevespi Aerosphere · 2019-10-17 · $13
  • Meals for Bevespi Aerosphere · 2019-08-29 · $12
  • Meals for Fasenra · 2019-07-11 · $23
  • Meals for Symbicort · 2019-06-12 · $24
  • Meals for Fasenra · 2019-03-22 · $16
  • Meals for Fasenra · 2019-03-06 · $8
  • Meals for Fasenra · 2019-03-06 · $13
  • Meals for Bevespi Aerosphere · 2019-02-13 · $13
  • Consulting for Fasenra · 2019-01-28 · $846
  • Meals for Fasenra · 2019-01-25 · $22
GenzymeDupixent$162
3 payments
  • Meals for Dupixent · 2019-12-04 · $122
  • Meals for Dupixent · 2019-10-09 · $19
  • Meals for Dupixent · 2019-06-26 · $21
GlaxoSmithKlineNucala$161
12 payments
  • Meals for Anoro · 2019-11-07 · $8
  • Meals for Trelegy Ellipta · 2019-10-03 · $7
  • Meals for Anoro · 2019-10-03 · $10
  • Meals for Anoro · 2019-08-29 · $11
  • Meals for Nucala · 2019-08-12 · $15
  • Meals for Nucala · 2019-07-22 · $6
  • Meals for Nucala · 2019-06-13 · $26
  • Meals for Nucala · 2019-06-05 · $22
  • Meals for Nucala · 2019-06-05 · $1
  • Meals for Nucala · 2019-04-11 · $16
  • Meals for Nucala · 2019-02-05 · $17
  • Meals for Trelegy Ellipta · 2019-01-09 · $23
Teva Pharmaceuticals USACinqair$154
3 payments
  • Meals for Cinqair · 2019-08-07 · $26
  • Meals for Cinqair · 2019-04-20 · $106
  • Meals for Cinqair · 2019-01-16 · $23
ALK-AbelloOdactra$147
3 payments
  • Meals for Odactra · 2019-10-02 · $20
  • Meals for Odactra · 2019-03-12 · $125
  • Meals for Odactra · 2019-01-02 · $2
Octapharma USACutaquig$122
1 payment
  • Meals for Cutaquig · 2019-08-21 · $122
Novartis PharmaceuticalsXolair$116
8 payments
  • Meals for Xolair · 2019-12-20 · $4
  • Meals for Xolair · 2019-12-11 · $23
  • Meals for Xolair · 2019-10-10 · $9
  • Meals for Xolair · 2019-09-11 · $20
  • Meals for Fevipiprant · 2019-08-29 · $11
  • Meals for Qge031 · 2019-07-26 · $18
  • Meals for Xolair · 2019-04-03 · $21
  • Meals for Xolair · 2019-03-28 · $10
Regeneron PharmaceuticalsDupixent$64
3 payments
  • Meals for Dupixent · 2019-11-10 · $25
  • Meals for Dupixent · 2019-09-30 · $18
  • Meals for Dupixent · 2019-04-22 · $22
PfizerEucrisa$46
3 payments
  • Meals for Panzyga · 2019-08-23 · $18
  • Meals for Eucrisa · 2019-04-19 · $14
  • Meals for Eucrisa · 2019-04-11 · $14
Genentech USAXolair$39
2 payments
  • Meals for Xolair · 2019-10-30 · $16
  • Meals for Xolair · 2019-05-15 · $23
KaleoAuvi-Q$28
2 payments
  • Meals for Auvi-Q · 2019-09-25 · $15
  • Meals for Auvi-Q · 2019-05-29 · $13
Horizon Therapeutics plcActimmune$25
1 payment
  • Meals for Actimmune · 2019-07-24 · $25
Mylan Specialty L.P.Yupelri$22
1 payment
  • Meals for Yupelri · 2019-05-02 · $22
Philips Electronics North AmericaReusable Vest$22
1 payment
  • Meals for Reusable Vest · 2019-03-20 · $22
Covis Pharma B.V.Alvesco$21
1 payment
  • Meals for Alvesco · 2019-04-17 · $21
Pharming HealthcareRuconest$19
1 payment
  • Meals for Ruconest · 2019-05-01 · $19

Research money

Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.

Research payments by company and study
Hikma Pharmaceuticals USA · Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study · 2019Their institution$211,260
GlaxoSmithKline, LLC. · A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para · 2024Their institution$194,331
Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2023Their institution$167,915
Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2022Their institution$156,134
CIPLA USA INC. · U-Fs-Mu-As3120 · 2019Their institution$144,089
SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Sar443765 in Adult Participants With Moderate To Severe Asthma · 2025Their institution$143,495
AstraZeneca Pharmaceuticals LP · A Randomized, Placebo-Controlled, Double-Blind, Multicenter, 12 Week, 3-Way, Partial-Replicate Crossover Pharmacodynamic Study To Assess the Equivalence of Budesonide and Albuterol (Bda) Delivered By Mdi Hfo Compared With Bda Delivered By Mdi Hfa in Participants With Asthma · 2025Their institution$141,546
AstraZeneca Pharmaceuticals LP · Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study To Assess Efficacy and Safety of Multiple Dose Levels of Inhaled Azd8630 · 2025Their institution$134,368
Novartis Pharmaceuticals Corporation · A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study To Assess the Efficacy and Safety of Csj117, When Added To Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. · 2021Their institution$131,921
AstraZeneca Pharmaceuticals LP · A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 To 52 Week Variable Length Study To Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler Mdi Relative To Budesonide and Formoterol Fumarate Mdi and Symbicort Pmdi in Adult and Adolescent Participants With Inadequately Controlled Asthma · 2022Their institution$116,976
Novartis Pharmaceuticals Corporation · A Three-Year, Multi-Center, Double-Blind, Extension Study To Evaluate the Long-Term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab'S Phase III Studies in Food Allergy · 2024Their institution$114,582
Teva Pharmaceuticals USA, Inc. · A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma · 2025Their institution$96,299
Teva Pharmaceuticals USA, Inc. · A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study To Evaluate the Efficacy and Safety of Tev-48574 in Adults With T2-Low/Non-T2 Severe Uncontrolled Asthma · 2021Their institution$85,647
GlaxoSmithKline, LLC. · A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Para · 2025Their institution$80,876
Teva Pharmaceuticals USA, Inc. · A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study To Assess the Safety, Efficacy and Pharmacodynamics of Tev 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma · 2021Their institution$77,950
SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-To-Severe Asthma · 2023Their institution$66,609
CIPLA USA INC. · A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, 4-Week Clinical Endpoint Bioequivalence Study Comparing Fluticasone Propionate/Salmeterol 100/50 Micro Gm Inhalation Powder With Advair Diskus 100/50 Micro Gm in Asthma Patients · 2020Their institution$60,657
AIMMUNE THERAPEUTICS, INC. · A Multicenter, Open-Label, Long-Term Safety Study of Ar101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study · 2020Their institution$52,025
AIMMUNE THERAPEUTICS, INC. · Phase 2 Study of Ar201 Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy · 2020Their institution$49,599
Novartis Pharmaceuticals Corporation · A Three-Year, Multi-Center, Double-Blind, Extension Study To Evaluate the Long-Term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab'S Phase III Studies in Food Allergy · 2023Their institution$45,238
GlaxoSmithKline, LLC. · A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm · 2021Their institution$44,038
SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-To-Severe Asthma · 2024Their institution$43,571
SANOFI US SERVICES INC. · A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma · 2021Their institution$39,148
Novartis Pharmaceuticals Corporation · A Multi Center Randomized Double Blind Active and Placebo Controlled Study To Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihis · 2020Their institution$35,647
Merck Sharp & Dohme Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Monthstudy To Evaluate the Efficacy and Safety of Mk-7264 in Adult Participants With Chroniccough Pn030 · 2019Their institution$35,033
AstraZeneca Pharmaceuticals LP · A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 To 52 Week Variable Length Study To Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler Mdi Relative To Budesonide and Formoterol Fumarate Mdi and Symbicort Pmdi in Adult and Adolescent Participants With Inadequately Controlled Asthma · 2023Their institution$33,878
AstraZeneca Pharmaceuticals LP · A Randomized, Placebo-Controlled, Double-Blind, Multicenter, 12 Week, 3-Way, Partial-Replicate Crossover Pharmacodynamic Study To Assess the Equivalence of Budesonide and Albuterol (Bda) Delivered By Mdi Hfo Compared With Bda Delivered By Mdi Hfa in Participants With Asthma · 2024Their institution$32,450
Teva Pharmaceuticals USA, Inc. · A Phase 2, Multicenter, Randomized, Double Blind, Placebo Controlled, Parallel Group Study To Assess the Safety, Efficacy and Pharmacodynamics of Tev 53275 Administered Subcutaneously in Adult Patients With Persistent Eosinophilic Asthma · 2022Their institution$32,352
Optinose US, Inc. · A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 G of Opn-375 Twice A Day Bid in Subjects With Chronic Sinusitis With Or Without the Presence of Nasal Polyps. Opn-Flu-Cs-3205. · 2019Their institution$30,818
GlaxoSmithKline, LLC. · A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou · 2022Their institution$30,596
AIMMUNE THERAPEUTICS, INC. · Phase 2 Study of Ar201 Oral Immunotherapy for Desensitization in Children, Adolescents, and Young Adults With Hen Egg Allergy · 2021Their institution$29,383
Teva Pharmaceuticals USA, Inc. · A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study To Evaluate the Efficacy and Safety of Tev-48574 in Adults With T2-Low/Non-T2 Severe Uncontrolled Asthma · 2022Their institution$28,452
CIPLA USA INC. · U-Fs-Mu-As3120 · 2020Their institution$28,167
GlaxoSmithKline, LLC. · A Phase III, Randomized, Double-Blind, Active Controlled, Parallel Gro · 2019Their institution$26,821
SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Sar443765 in Adult Participants With Moderate To Severe Asthma · 2024Their institution$24,018
Optinose US, Inc. · A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 G of Opn-375 Twice A Day (Bid) in Subjects With Chronic Sinusitis With Or Without the Presence of Nasal Polyps. Opn-Flu-Cs-3205. · 2020Their institution$22,095
Teva Pharmaceuticals USA, Inc. · A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study To Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma · 2025Their institution$21,792
Hikma Pharmaceuticals USA · Fluticasone / Salmeterol Powder, 100mcg/50mcg Multicenter Clinical Endpoint Study · 2020Their institution$20,340
SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Week Proof-of-Concept (Poc) Study To Assess the Efficacy, Safety, and Tolerability of Sar440340 and the Coadministration of Sar440340 · 2019Their institution$20,195
SANOFI US SERVICES INC. · A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma · 2023Their institution$19,120
Novartis Pharmaceuticals Corporation · A Multi Center Randomized Double Blind Active and Placebo Controlled Study To Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihistamines · 2021Their institution$18,264
AIMMUNE THERAPEUTICS, INC. · A Multicenter, Open-Label, Long-Term Safety Study of Ar101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study · 2021Their institution$17,966
Novartis Pharmaceuticals Corporation · A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study To Assess the Efficacy and Safety of Csj117, When Added To Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. · 2020Their institution$17,465
SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-To-Severe Asthma · 2025Their institution$17,388
CIPLA USA INC. · 2023Their institution$16,539
GlaxoSmithKline, LLC. · A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm · 2022Their institution$16,523
Teva Pharmaceuticals USA, Inc. · A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study To Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma · 2024Their institution$15,088
Optinose US, Inc. · A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 G of Opn-375 Twice A Day (Bid) in Subjects With Chronic Sinusitis With Or Without the Presence of Nasal Polyps. Opn-Flu-Cs-3205. · 2022Their institution$15,077
Teva Pharmaceuticals USA, Inc. · A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Proof-of-Concept Study To Evaluate the Efficacy and Safety of Tev-48574 in Adults With T2-Low/Non-T2 Severe Uncontrolled Asthma · 2020Their institution$14,803
GlaxoSmithKline, LLC. · A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou · 2021Their institution$12,785
Novartis Pharmaceuticals Corporation · A Multi-Center, Double-Blinded and Open-Label Extension Study To Evaluate the Efficacy and Safety of Ligelizumab As Retreatment, Self-Administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies Cqge031c2302, Cqge031c2303, Cqge031c2202 Or Cqge031c1301 · 2021Their institution$12,475
AstraZeneca Pharmaceuticals LP · A Phase II, Randomized, Double-Blind, Single-Dose, Placebo-Controlled, 3-Period, 3-Treatment, Crossover, Multicenter Study To Compare the Bronchodilatory Effect and Safety of Pt007 As Mdi To Placebo Mdi and Open-Label Ventolin Evohaler in Adult Participants With Asthma Mitchell · 2025Their institution$11,783
CHIESI USA, INC. · Ccd-05993aa3-01 · 2019Their institution$10,989
SANOFI US SERVICES INC. · A Randomized, Multicenter, 3-Arm, Double-Blind, Placebo-Controlled Study To Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of Sar439794 in Peanut Alle · 2019Their institution$10,637
SANOFI US SERVICES INC. · A Long-Term Extension Study To Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Amlitelimab in Adult Participants With Moderate-To-Severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study · 2023Their institution$10,500
SANOFI US SERVICES INC. · A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose Ranging Study To Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-To-Severe Asthma · 2022Their institution$10,500
Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2024Their institution$10,486
Novartis Pharmaceuticals Corporation · A Multi Center Randomized Double Blind Active and Placebo Controlled Study To Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihis · 2019Their institution$8,877
SANOFI US SERVICES INC. · Open-Label Extension Study To Evaluate the Long-Term Safety and Tolerability of Dupilumab in Patients With Asthma Who Participated in A Previous Dupilumab Asthma Clinical Study · 2019Their institution$8,858
GlaxoSmithKline, LLC. · A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul · 2021Their institution$8,400
Novartis Pharmaceuticals Corporation · A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study To Assess the Efficacy and Safety of Csj117, When Added To Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. · 2022Their institution$8,176
SANOFI US SERVICES INC. · A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma · 2022Their institution$7,304
Merck Sharp & Dohme Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study To Evaluate the Efficacy and Safety of Mk-7264 in Adult Participants With Chronic Cough Pn030 · 2021Their institution$6,783
AstraZeneca Pharmaceuticals LP · A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of Pt001 To Placebo and Open-Label Spiriva Respimat in Subjects With Persistent Asthma · 2020Their institution$6,756
SANOFI US SERVICES INC. · Open-Label, Interventional, Cohort Study To Evaluate Long-Term Safety of Dupilumab in Patients With Moderate To Severe Asthma Who Completed the Traverse-Lts12551 Clinical Trial · 2020Their institution$6,324
Novartis Pharmaceuticals Corporation · A Multi-Center, Double-Blinded and Open-Label Extension Study To Evaluate the Efficacy and Safety of Ligelizumab As Retreatment, Self-Administered Therapy and Monotherapy in Chronic Spontaneous Urticaria Patients Who Completed Studies Cqge031c2302, Cqge03 · 2022Their institution$6,198
Novartis Pharmaceuticals Corporation · A 52 Week, Multi-Center, Randomized, Double-Blind Placebo-Controlled Study To Assess the Clinical Efficacy and Safety of Ligelizumab (Qge031) in Decreasing the Sensitivity To Peanuts in Patients With Peanut Allergy · 2021Their institution$5,870
AIMMUNE THERAPEUTICS, INC. · A Multicenter, Open-Label, Long-Term Safety Study of Ar101 Characterized Oral Desensitization Immunotherapy in Subjects Who Participated in A Prior Ar101 Study · 2022Their institution$5,643
GlaxoSmithKline, LLC. · A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou · 2025Their institution$4,898
GlaxoSmithKline, LLC. · A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou · 2024Their institution$3,913
AstraZeneca Pharmaceuticals LP · A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 To 52 Week Variable Length Study To Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler Mdi Relative To Budesonide and Formoterol Fumarate Mdi and Symbicort Pmdi in Adult and Adolescent Participants With Inadequately Controlled Asthma · 2025Their institution$3,874
SANOFI US SERVICES INC. · A Randomized Double Blind Placebo Controlled Parallel Goup 12 Week Proof of Concept Study To Assess the Efficacy, Safety, and Tolerability of Sar440340 and the Coadministration of Sar440340 and Dupilu · 2020Their institution$3,500
AIMMUNE THERAPEUTICS, INC. · 2023Their institution$3,386
SANOFI US SERVICES INC. · A Phase 4, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of the Effect of Dupilumab on Sleep Disturbance in Patients With Uncontrolled Persistent Asthma · 2024Their institution$3,225
AstraZeneca Pharmaceuticals LP · A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of Pt001 To Placebo and Open-Label Spiriva Respimat in Subjects With Persistent Asthma · 2019Their institution$3,009
Novartis Pharmaceuticals Corporation · A Three-Year, Multi-Center, Double-Blind, Extension Study To Evaluate the Long-Term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab'S Phase III Studies in Food Allergy · 2025Their institution$2,669
SANOFI US SERVICES INC. · A Randomized Multicenter 3-Arm Double Blind Placebo Controlled Study To Assess the Safety Tolerability and Pharmacodynamics of Repeated Sublingual Daily Adminstration of Sar439794 in Peanut Allergic A · 2020Their institution$2,122
Novartis Pharmaceuticals Corporation · A 12-Week, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Study To Assess the Efficacy and Safety of Csj117, When Added To Existing Asthma Therapy in Patients ? 18 Years of Age With Severe Uncontrolled Asthma. · 2023Their institution$2,000
SANOFI US SERVICES INC. · A Randomized, Multicenter, 3-Arm, Double-Blind, Placebo-Controlled Study To Assess the Safety, Tolerability and Pharmacodynamics of Repeated Sublingual Daily Administration of Sar439794 in Peanut Alle · 2020Their institution$1,797
Merck Sharp & Dohme Corporation · A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study To Evaluate the Efficacy and Safety of Mk-7264 in Adult Participants With Chronic Cough Pn030 · 2020Their institution$1,480
AstraZeneca Pharmaceuticals LP · Multicentre, Double-Blind, Randomized, Parallel Group, Phase 3 Safety Extension Study To Evaluate the Safety and Tolerability of Benralizumab (Medi-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus Long-Acting Beta2 Agonist Bora · 2019Their institution$1,387
SANOFI US SERVICES INC. · A Randomized Multicenter 3-Arm Double Blind Placebo Controlled Study To Assess the Safety Tolerability and Pharmacodynamics of Repeated Sublingual Daily Adminstration of Sar439794 in Peanut Allergic A · 2019Their institution$1,337
Novartis Pharmaceuticals Corporation · A Multi Center Randomized Double Blind Active and Placebo Controlled Study To Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihis · 2022Their institution$1,232
Optinose US, Inc. · A 24-Week Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of Intranasal Administration of 186 and 372 G of Opn-375 Twice A Day (Bid) in Subjects With Chronic Sinusitis With Or Without the Presence of Nasal Polyps. Opn-Flu-Cs-3205. · 2021Their institution$1,227
CIPLA USA INC. · 2024Their institution$1,000
Novartis Pharmaceuticals Corporation · A 52-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Study To Assess Efficacy and Safety of Remibrutinib (Lou064) in Adult and Adolescent Participants With Ige-Mediated Food Allergy. · 2025Their institution$910
SANOFI US SERVICES INC. · Open-Label, Interventional, Cohort Study To Evaluate Long-Term Safety of Dupilumab in Patients With Moderate To Severe Asthma Who Completed the Traverse-Lts12551 Clinical Trial · 2019Their institution$600
AstraZeneca Pharmaceuticals LP · A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 To 52 Week Variable Length Study To Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler Mdi Relative To Budesonide and Formoterol Fumarate Mdi and Symbicort Pmdi in Adult and Adolescent Participants With Inadequately Controlled Asthma · 2024Their institution$371
GlaxoSmithKline, LLC. · A 52-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel-Grou · 2023Their institution$232
Merck Sharp & Dohme Corporation · A 12-Week Study To Assess the Efficacy and Safety Ofaf-219 Mk-7264 in Subjects With Treatment Refractorychronic Cough · 2021Their institution$61
Novartis Pharmaceuticals Corporation · A Multi Center Randomized Double Blind Active and Placebo Controlled Study To Investigate the Efficacy and Safety of Ligelizumab Qge031 in the Treatment of Chronic Spontaneous Urticaria Csu in Adolescents and Adults Inadequately Controlled With H1 Antihistamines · 2023Their institution$60

Professional record

NPI
1063528321
Licence
CA G39891California G39891: Current · expires 2028-07-31
Trained
University of Texas Medical Branch at Galveston, 1977
Video visits
Lists video visits
Gender
Male
More record details
Sole proprietor
No
Taxonomy
Federal specialty code 207K00000X (207K00000X)
Mailing address
4050 Moorpark Ave, San Jose, CA, 95117
NPI first listed
2006-08-21
NPI last updated
2016-02-25

This is when the NPI record was last certified, not a medical board exam.